Table 2.
Clinical parameters of glioblastoma multiforme (GBM) patients (n = 43).
| Patients’ Characteristics | |
|---|---|
| Sex | |
| female | 18/41.9% |
| male | 25/58.1% |
| Age (median, quartiles) | 59.0 years (49.0–70.0 years) |
| ECOG | |
| 0 | 22/51.2% |
| 1 | 17/39.5% |
| >1 | 4/9.3% |
| Tumor Characteristics | |
| Volume (median, quartiles) | 30.1 cm3 (16.2–54.3 cm3) |
| Localization | |
| left hemisphere | 24/55.8% |
| right hemisphere | 16/37.2% |
| both hemispheres | 3/7.0% |
| Localization (lobe) | |
| frontal | 13/30.2% |
| occipital | 5/11.6% |
| temporal | 7/16.3% |
| parietal | 5/11.6% |
| multiple | 13/30.2% |
| MGMT promoter methylation 1 | |
| unmethylated | 10/31.3% |
| methylated | 22/68.7% |
| Ki67 staining (median, quartiles) | 25% (20–30) |
| Therapy | |
| Time from diagnosis to therapy | |
| 0–7 days | 27/62.9% |
| 8–14 days | 9/20.9% |
| >14 days | 7/16.2% |
| Surgical intervention | |
| biopsy | 6/14.0% |
| complete resection | 9/20.9% |
| incomplete resection | 28/65.1% |
| Radiation therapy | |
| yes | 40/93.0% |
| no | 3/7.0% |
| TMZ chemotherapy | |
| yes | 35/81.4% |
| no | 8/18.6% |
| Relapse and Outcome | |
| PFS 2 | |
| 0–6 months | 2/5.6% |
| >6 months | 34/94.4% |
| Relapse | |
| primarily multifocal | 7/16.3% |
| local | 24/55.8% |
| multifocal | 12/27.9% |
| OS | |
| 0–6 months | 4/9.3% |
| >6 months | 39/90.7% |
Given are the absolute numbers of the GBM patients in each group and the percentage of the analyzed population. 1 Due to a lack of sufficient tissue samples, the MGMT promoter methylation status could not be re-evaluated for some patients. 2 Some patients did not match criteria for tumor progression and, therefore, were excluded from the PFS analysis. ECOG = Eastern Cooperative Oncology Group score; MGMT = O6-methylguanine-DNA methyltransferase; TMZ = Temozolomide; PFS = progression-free survival; OS = overall survival.